Real world use of ixekizumab is associated with reductions in concomitant medications among biologic-experienced or biologic-na ïve patients with psoriasis

Background: Psoriasis (PsO) is often treated with topical and oral corticosteroids, topical noncorticosteroids, phototherapy/PUVA or nonbiologic systemic medications. Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, is used for the treatment of moderate-to-severe PsO. In this analysis, we evaluated the treatment patterns of concomitant medications in patients (pts) with PsO who switched from any previous medications to IXE.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research